Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skin Cleanser Combination No.1
- Development stage
- Unknown
- Lead developer
- Boston Children's Hospital
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral, Topical
01
Overview
Skin Cleanser Combination No.1 is a combination topical regimen used for skin decolonization, specifically targeting Staphylococcus aureus in patients with atopic dermatitis and related skin disorders. The regimen includes the use of sulfamethoxazole/trimethoprim (an oral antibiotic combination), mupirocin ointment (a topical antibiotic), and chlorhexidine (an antiseptic cleanser). Its primary mechanism is to reduce S. aureus colonization on the skin, which may decrease disease severity and modulate immune responses in affected individuals[1][4]. This combination is being studied in phase 4 clinical trials for its efficacy in reducing disease severity in atopic dermatitis.
- Brand names
- Skin Cleanser Combination No.1
02
Targets
IleRS (Isoleucyl-tRNA synthetase)DHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on Skin Cleanser Combination No.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skin Cleanser Combination No.1.